Stryker (NYSE:SYK) Hits New 52-Week Low – Here’s Why

Shares of Stryker Corporation (NYSE:SYK) hit a new 52-week low during trading on Tuesday . The company traded as low as $290.22 and last traded at $291.2090, with a volume of 3089801 shares trading hands. The stock had previously closed at $294.73.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price target on shares of Stryker in a report on Friday. Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday. Robert W. Baird set a $385.00 price target on Stryker in a report on Friday. Finally, William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Stock Down 1.2%

The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The firm has a market cap of $111.53 billion, a price-to-earnings ratio of 33.70, a price-to-earnings-growth ratio of 1.73 and a beta of 0.80. The stock’s 50 day moving average is $345.67 and its 200 day moving average is $356.80.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts forecast that Stryker Corporation will post 14.89 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were given a $0.88 dividend. The ex-dividend date was Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s payout ratio is 40.74%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Sankala Group LLC acquired a new position in Stryker in the fourth quarter worth approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the fourth quarter worth approximately $27,000. Finally, DJE Kapital AG acquired a new position in Stryker in the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.